United Therapeutics (NASDAQ:UTHR) PT Raised to $350.00 at TD Cowen

United Therapeutics (NASDAQ:UTHR) had its price target upped by equities research analysts at TD Cowen from $270.00 to $350.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The firm currently has a “buy” rating on the biotechnology company’s stock. TD Cowen’s price objective suggests a potential upside of 8.91% from the stock’s current price.

Several other brokerages have also weighed in on UTHR. UBS Group raised their target price on United Therapeutics from $300.00 to $370.00 and gave the stock a “buy” rating in a research report on Monday, July 8th. JPMorgan Chase & Co. lifted their price target on United Therapeutics from $280.00 to $300.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 21st. HC Wainwright reiterated a “buy” rating and issued a $300.00 target price on shares of United Therapeutics in a research note on Thursday, May 2nd. Oppenheimer lifted their price target on United Therapeutics from $375.00 to $400.00 and gave the company an “outperform” rating in a research note on Thursday, May 2nd. Finally, StockNews.com downgraded United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, June 20th. Two analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $321.55.

United Therapeutics Stock Performance

NASDAQ UTHR opened at $321.38 on Thursday. The stock has a fifty day simple moving average of $290.04 and a 200-day simple moving average of $249.71. United Therapeutics has a twelve month low of $208.62 and a twelve month high of $330.00. The stock has a market cap of $14.26 billion, a PE ratio of 15.20, a P/E/G ratio of 1.45 and a beta of 0.55. The company has a current ratio of 3.77, a quick ratio of 3.64 and a debt-to-equity ratio of 0.04.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 EPS for the quarter, beating analysts’ consensus estimates of $5.63 by $0.54. The company had revenue of $677.70 million during the quarter, compared to analysts’ expectations of $620.31 million. United Therapeutics had a return on equity of 18.72% and a net margin of 42.05%. United Therapeutics’s revenue for the quarter was up 33.7% on a year-over-year basis. During the same period last year, the business posted $4.86 EPS. Equities analysts anticipate that United Therapeutics will post 24.73 earnings per share for the current year.

Insider Transactions at United Therapeutics

In related news, CEO Martine A. Rothblatt sold 3,600 shares of the company’s stock in a transaction on Wednesday, July 10th. The stock was sold at an average price of $326.35, for a total value of $1,174,860.00. Following the completion of the transaction, the chief executive officer now directly owns 130 shares in the company, valued at $42,425.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other United Therapeutics news, Director Christopher Causey sold 2,240 shares of the company’s stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $259.91, for a total transaction of $582,198.40. Following the completion of the sale, the director now directly owns 4,185 shares in the company, valued at $1,087,723.35. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Martine A. Rothblatt sold 3,600 shares of the stock in a transaction dated Wednesday, July 10th. The shares were sold at an average price of $326.35, for a total value of $1,174,860.00. Following the completion of the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at approximately $42,425.50. The disclosure for this sale can be found here. Insiders sold a total of 100,884 shares of company stock valued at $27,931,991 over the last three months. 12.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On United Therapeutics

A number of large investors have recently modified their holdings of UTHR. Rise Advisors LLC acquired a new stake in United Therapeutics during the 1st quarter valued at approximately $32,000. GAMMA Investing LLC bought a new stake in United Therapeutics during the 4th quarter valued at $43,000. Benjamin F. Edwards & Company Inc. raised its stake in United Therapeutics by 63.6% during the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 301 shares of the biotechnology company’s stock valued at $69,000 after acquiring an additional 117 shares in the last quarter. Janiczek Wealth Management LLC raised its stake in United Therapeutics by 21.1% during the 1st quarter. Janiczek Wealth Management LLC now owns 482 shares of the biotechnology company’s stock valued at $111,000 after acquiring an additional 84 shares in the last quarter. Finally, Blue Trust Inc. increased its position in shares of United Therapeutics by 10.0% during the 4th quarter. Blue Trust Inc. now owns 504 shares of the biotechnology company’s stock valued at $114,000 after purchasing an additional 46 shares during the period. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.